
Link's Take On The ...


| Price and Volume | |
|---|---|
| Recent Price | 2.77 |
| 52 Week High | 4.07 |
| 52 Week Low | 1.03 |
| Avg. Daily Vol. (Mil) | 0.29 |
| Beta (3 year) | 1.71 |
| Share Related Items | |
| Mkt Cap (Mil) | 64.30 |
| Shares Out (Mil) | 23.21 |
| Float (Mil) | 13.74 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.70 |
| Current Ratio | 1.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.49 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 30.47 |
| Price/Book | 28.24 |
| Price/Cash Flow | -8.20 |
| Per Share Data | |
| Earnings | -0.52 |
| Sales | 0.09 |
| Book Value | 0.10 |
| Cash Flow | -0.34 |
| Business Summary | |
|---|---|
| Vermillion, Inc., discovers, develops and commercializes diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. | |
| General Information | |
| 12117 Bee Caves Road
Building Three Austin, TX 78738 |
|
| www.vermillion.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 20 | |
| CEO: Thomas H. Mclain | |
| Short Interest | |
| Current Month (Mil) | 0.67 |
| Previous Month (Mil) | 0.39 |
| Short Interest Ratio (Days) | 1.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -122.10 |
| Return on Investments | -348.00 |
| Profitability | |
| Gross Margin | 97.90 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |